彭布罗利珠单抗
医学
生物标志物
肿瘤科
前瞻性队列研究
内科学
癌症
免疫疗法
生物
生物化学
作者
Wei Nie,Jie Qian,Bo Zhang,Hua Zhong,Baohui Han
出处
期刊:Lancet Oncology
[Elsevier BV]
日期:2020-12-01
卷期号:21 (12): e551-e551
被引量:3
标识
DOI:10.1016/s1470-2045(20)30617-3
摘要
We read with great interest the Article by Aurélien Marabelle and colleagues 1 Marabelle A Fakih M Lopez J et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21: 1353-1365 Summary Full Text Full Text PDF PubMed Scopus (535) Google Scholar on the biomarker analysis of the KEYNOTE-158 study. The authors indicated that high tissue tumour mutational burden (tTMB-high) could be a predictive biomarker for response to pembrolizumab monotherapy in patients with previously treated, advanced solid tumours. We applaud the authors' efforts but would like to raise some concerns with the methods used. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studytTMB-high status identifies a subgroup of patients who could have a robust tumour response to pembrolizumab monotherapy. tTMB could be a novel and useful predictive biomarker for response to pembrolizumab monotherapy in patients with previously treated recurrent or metastatic advanced solid tumours. Full-Text PDF Tumour mutational burden in treatment-resistant tumours – Authors' replyWe thank Wei Nie and colleagues for their interest in our manuscript describing the association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab in the KEYNOTE-158 study.1 They raise a number of interesting points that we acknowledge while also noting that, for the reasons outlined below, the analytical approach we pursued was appropriate. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI